Pharmacology of Calcitonin

Introduction/Overview

Calcitonin is a polypeptide hormone primarily involved in calcium and bone metabolism. Originally discovered in 1961 by Copp and Cheney, it is secreted by the parafollicular cells (C-cells) of the thyroid gland in mammals. The hormone plays a significant, though non-essential, role in calcium homeostasis, acting as a physiological antagonist to parathyroid hormone (PTH). Its pharmacological utility is derived from its potent ability to inhibit osteoclastic bone resorption, leading to a rapid decrease in serum calcium concentrations. While endogenous human calcitonin exists, the agents used therapeutically are primarily synthetic or semi-synthetic analogs, with calcitonin salmon being the most widely employed due to its greater receptor affinity and prolonged duration of action compared to the human form.

The clinical relevance of calcitonin has evolved over decades. It has been established as a therapeutic agent for disorders characterized by excessive bone resorption, most notably Paget’s disease of bone, hypercalcemia of malignancy, and postmenopausal osteoporosis. However, its role in the long-term management of osteoporosis has diminished with the advent of more potent antiresorptive agents like bisphosphonates and denosumab. Despite this, calcitonin retains a niche in clinical practice, particularly for its analgesic properties in acute pain associated with osteoporotic vertebral fractures and for the management of hypercalcemic emergencies. Its intranasal formulation offers a non-invasive route of administration, which can be advantageous in specific patient populations.

The following learning objectives are intended to guide the understanding of this chapter:

• Describe the physiological role of endogenous calcitonin and differentiate it from the pharmacological actions of therapeutic analogs.
• Explain the molecular mechanism of action of calcitonin, including receptor binding and intracellular signaling pathways in osteoclasts and renal tubules.
• Outline the pharmacokinetic properties of different calcitonin formulations (injectable and intranasal) and their implications for dosing regimens.
• Identify the approved therapeutic indications for calcitonin and analyze the evidence supporting its use, including its relative position in treatment hierarchies.
• Evaluate the major adverse effect profile, contraindications, and special considerations for calcitonin use across diverse patient populations.

Classification

Therapeutic calcitonin is classified as an antiresorptive agent or a hypocalcemic hormone. It belongs to the broader category of drugs affecting bone metabolism.

Chemical and Source Classification

Calcitonin is a 32-amino acid linear polypeptide hormone. The amino acid sequence varies significantly among species, which impacts its biological potency and immunogenicity. Pharmacological preparations are categorized based on their source:

• Calcitonin Salmon (Synthetic or Semi-synthetic): This is the most commonly used therapeutic form. Salmon calcitonin differs from human calcitonin at 16 of the 32 amino acid positions. These structural differences confer a higher binding affinity for the human calcitonin receptor and a longer plasma half-life, resulting in greater and more prolonged biological activity. It is available as a synthetic or semi-synthetic product.
• Human Calcitonin: Synthetic human calcitonin is identical to the endogenous hormone. While available in some markets, it is generally considered less potent than the salmon analog and is used less frequently.
• Porcine Calcitonin: Rarely used today, it was an earlier formulation with lower potency compared to salmon calcitonin.

Formulation and Route Classification

The drug is available in several formulations, which dictate its route of administration and clinical application:

• Parenteral Formulations: These include subcutaneous and intramuscular injections. They provide systemic bioavailability and are typically used for acute conditions like hypercalcemia or when a rapid onset of action is required.
• Intranasal Formulation: A metered-dose spray that delivers calcitonin salmon through the nasal mucosa. This route offers convenience and improves patient compliance for chronic conditions like osteoporosis, albeit with lower and more variable systemic bioavailability compared to injections.

Mechanism of Action

The pharmacological effects of calcitonin are mediated through its action on specific high-affinity receptors, primarily located on osteoclasts and renal tubular cells. Its mechanism is best understood as a rapid inhibition of bone resorption and a modest increase in renal calcium excretion.

Receptor Interactions

Calcitonin exerts its effects by binding to the calcitonin receptor (CTR), a member of the class B G-protein-coupled receptor (GPCR) family. The receptor exists in multiple isoforms due to alternative splicing. Upon agonist binding, the CTR primarily couples to the G_s protein, leading to activation of adenylate cyclase and a subsequent increase in intracellular cyclic adenosine monophosphate (cAMP). In some cell types, it may also couple to G_q proteins, activating the phospholipase C (PLC) pathway and increasing inositol trisphosphate (IP₃) and diacylglycerol (DAG), which mobilizes intracellular calcium. The salmon analog possesses a higher binding affinity for the human CTR compared to human calcitonin, resulting in more potent and sustained receptor activation.

Cellular and Molecular Mechanisms in Bone

The most significant pharmacological action is the direct inhibition of osteoclast activity. Mature osteoclasts possess a high density of CTRs on their plasma membranes, particularly on the ruffled border facing the bone surface.

• Inhibition of Resorptive Activity: Receptor activation leads to a rapid retraction of the osteoclast’s ruffled border, the structure responsible for secreting acids and proteolytic enzymes onto the bone surface. This retraction is mediated through cytoskeletal rearrangements driven by the cAMP and calcium signaling pathways.
• Reduction in Osteoclast Number: Chronically, calcitonin may reduce osteoclast proliferation and promote apoptosis, thereby decreasing the total number of active bone-resorbing cells.
• Inhibition of Acid and Enzyme Secretion: The hormone suppresses the secretion of hydrogen ions (via the proton pump) and lysosomal enzymes (such as cathepsin K) into the resorption lacuna.

The net effect is a rapid decrease in the release of calcium, phosphate, and hydroxyproline (a bone matrix breakdown product) from bone into the extracellular fluid, leading to a fall in serum calcium and phosphate levels.

Renal Mechanisms

Calcitonin acts on receptors in the distal convoluted tubules and possibly the thick ascending limb of the loop of Henle in the kidney.

• Increased Calcium Excretion: It promotes calciuresis (excretion of calcium in urine) and phosphaturia (excretion of phosphate). The mechanism involves inhibition of tubular reabsorption of these ions. The effect on calcium is modest and transient, often overshadowed by the more potent hypocalcemic action derived from inhibiting bone resorption.
• Other Renal Effects: Calcitonin also increases the excretion of sodium, potassium, and magnesium to a lesser extent, and may have a mild diuretic effect.

Central Nervous System and Analgesic Effects

An important, though not fully elucidated, property of calcitonin is its analgesic effect, particularly for bone pain. This action appears to be independent of its effects on bone turnover. Proposed mechanisms include:

• Direct action on calcitonin receptors in central nervous system regions involved in pain perception, such as the periaqueductal gray matter.
• Modulation of beta-endorphin release.
• Inhibition of prostaglandin and cytokine synthesis.
• Alteration of calcium fluxes in neuronal cells.

This central analgesic effect underpins its use for the pain of acute vertebral fractures and Paget’s disease.

Pharmacokinetics

The pharmacokinetic profile of calcitonin varies considerably between formulations and routes of administration. As a polypeptide, it is susceptible to degradation by proteolytic enzymes, which influences its absorption and distribution.

Absorption

Parenteral Administration (Subcutaneous/Intramuscular): Absorption from injection sites is rapid and relatively complete. Bioavailability approaches 70% or more. The time to reach peak plasma concentration (t_max) is approximately 15 to 30 minutes following subcutaneous injection.

Intranasal Administration: Absorption occurs through the nasal mucosa. Systemic bioavailability is low and highly variable, typically ranging from 3% to 25% of the administered dose. This variability is influenced by factors such as nasal inflammation, mucosal integrity, and technique of administration. The t_max is slightly longer than with injections, occurring within 30 to 40 minutes.

Oral Administration: Calcitonin is not effective orally due to extensive proteolytic degradation in the gastrointestinal tract.

Distribution

Following absorption, calcitonin is distributed rapidly into the extracellular fluid. Its volume of distribution is relatively small, approximately 0.15 to 0.3 L/kg, indicating limited tissue penetration beyond the plasma and interstitial fluid. It does not cross the blood-brain barrier in significant quantities, though the central effects suggest some access or action at circumventricular organs. Protein binding is not considered significant.

Metabolism and Elimination

Calcitonin undergoes extensive catabolism, primarily in the kidneys, but also in the blood, liver, and other peripheral tissues. The metabolic process involves proteolytic degradation at the N- and C-termini, rendering the hormone inactive. The kidneys play a dominant role; they not only filter the peptide but also extract and degrade it via peritubular uptake and metabolism in proximal tubular cells. Consequently, renal impairment can significantly alter calcitonin pharmacokinetics.

The elimination half-life (t_1/2) differs between forms. For calcitonin salmon administered parenterally, the t_1/2 is approximately 60 to 90 minutes. The half-life of human calcitonin is shorter, around 10 to 15 minutes. The intranasal route exhibits a similar elimination half-life once the drug is absorbed systemically. The total body clearance is high, often exceeding renal plasma flow, indicating substantial extrarenal metabolism.

Pharmacokinetic-Pharmacodynamic Relationships

The hypocalcemic effect does not directly correlate with plasma drug concentrations in a simple linear fashion. The effect on osteoclasts is rapid, and the duration of biological action often exceeds the plasma half-life. This may be due to prolonged receptor occupancy or sustained intracellular signaling events initiated by the hormone-receptor interaction. For chronic conditions like osteoporosis, the effect on biochemical markers of bone resorption (e.g., urinary N-telopeptide) is observed with daily or alternate-day dosing, despite the short plasma t_1/2.

Therapeutic Uses/Clinical Applications

The therapeutic applications of calcitonin are centered on conditions characterized by accelerated bone turnover or elevated serum calcium.

Approved Indications

Paget’s Disease of Bone (Osteitis Deformans): Calcitonin is an established treatment for symptomatic Paget’s disease, particularly when there is bone pain, high-output cardiac failure, or neurological compromise due to skeletal deformity. It effectively reduces elevated bone turnover, as evidenced by decreases in serum alkaline phosphatase and urinary hydroxyproline. It can alleviate bone pain and may improve neurological symptoms. However, bisphosphonates are now considered first-line due to their greater potency and more prolonged suppression of disease activity.

Hypercalcemia of Malignancy: Parenteral calcitonin (usually salmon) is used as adjunctive therapy in the acute management of severe hypercalcemia. Its onset of action is rapid (within hours), making it useful while awaiting the slower effects of rehydration, loop diuretics, and bisphosphonates. It is often combined with intravenous bisphosphonates and glucocorticoids (which can enhance its hypocalcemic effect). Tachyphylaxis, a diminishing response with repeated dosing, frequently develops after 48 to 72 hours, limiting its utility to short-term management.

Postmenopausal Osteoporosis: Calcitonin is approved for the treatment of established osteoporosis in postmenopausal women who are more than five years post-menopause. It has been shown to increase lumbar spine bone mineral density (BMD) modestly and, more notably, to reduce the risk of new vertebral fractures. Its efficacy in reducing non-vertebral or hip fractures is less well-established compared to bisphosphonates or denosumab. Its primary niche is in patients who cannot tolerate other antiresorptives or for the short-term management of acute pain from osteoporotic vertebral fractures, leveraging its analgesic properties.

Off-Label and Investigational Uses

• Acute Pain of Vertebral Fractures: The analgesic effect is commonly utilized off-label, with both injectable and intranasal forms providing pain relief that may be independent of fracture healing.
• Complex Regional Pain Syndrome (CRPS) Type I: Some evidence supports its use for pain and dystrophic changes in early CRPS.
• Osteoarthritis and Bone Metastases Pain: Investigated for its analgesic potential in these conditions, though evidence remains limited.
• Prevention of Postmenopausal Bone Loss: While effective, it is not typically a first-line agent for prevention due to the availability of other options.

Adverse Effects

The adverse effect profile of calcitonin is generally mild to moderate and often route-dependent.

Common Side Effects

With Parenteral Administration: Systemic effects are more pronounced.

• Gastrointestinal: Nausea, vomiting, anorexia, and abdominal pain occur in a significant minority of patients, especially with initial doses. These effects often diminish with continued therapy.
• Flushing: A transient warmth or flushing of the face, ears, hands, and feet is very common shortly after injection.
• Local Reactions: Inflammation, pain, or swelling at the injection site.

With Intranasal Administration: Local nasal effects predominate.

• Rhinitis: Nasal irritation, dryness, redness, itching, and epistaxis (nosebleeds) are frequent.
• Other: Headache, back pain, and arthralgias have been reported. Systemic effects like nausea and flushing are less common than with injections.

Serious/Rare Adverse Reactions

• Hypersensitivity Reactions: Anaphylaxis and other allergic reactions are rare but possible, particularly with parenteral formulations. Skin testing may be considered in patients with suspected sensitivity.
• Antibody Formation: Non-neutralizing antibodies develop in a substantial proportion of patients receiving salmon calcitonin, especially with long-term use. These antibodies rarely lead to clinical resistance (tachyphylaxis). Neutralizing antibodies that block biological activity are uncommon but can occur.
• Urinary Frequency: May be related to its mild diuretic effect.

Black Box Warnings and Major Safety Concerns

Regulatory agencies have issued warnings regarding a potential increased risk of malignancies with long-term use of calcitonin salmon. Meta-analyses of clinical trial data suggested a small but statistically significant increase in the incidence of various cancers among calcitonin-treated patients compared to placebo. The absolute risk increase appears low, and a causal relationship remains uncertain. However, this concern has led to restrictions on its long-term use for osteoporosis in many regions, reserving it primarily for short-term pain management in acute bone loss scenarios. There is no black box warning for its use in Paget’s disease or hypercalcemia, where treatment duration is typically short.

Drug Interactions

Formal pharmacokinetic drug interaction studies are limited due to its polypeptide nature and metabolic pathway. Most interactions are pharmacodynamic in nature.

Major Drug-Drug Interactions

• Lithium: Calcitonin may reduce serum lithium concentrations, potentially leading to a decrease in its therapeutic effect. Serum lithium levels should be monitored closely if calcitonin is initiated or discontinued.
• Other Hypocalcemic Agents: Concomitant use with potent hypocalcemic drugs like bisphosphonates, denosumab, or plicamycin may have additive effects, increasing the risk of hypocalcemia. Serum calcium monitoring is advisable.
• Loop Diuretics (e.g., Furosemide): When used together in the management of hypercalcemia, the calciuretic effects may be additive, enhancing calcium excretion. This is often a therapeutic goal, but requires careful monitoring of fluid and electrolyte status.

Contraindications

• Known Hypersensitivity: Contraindicated in patients with a history of anaphylaxis or severe allergy to calcitonin-salmon or any component of the formulation.
• Severe, Uncorrected Hypocalcemia: Its use is contraindicated as it will further lower serum calcium levels.

Special Considerations

Use in Pregnancy and Lactation

Pregnancy (Category C): Animal reproduction studies have shown adverse fetal effects. There are no adequate and well-controlled studies in pregnant women. Calcitonin does not cross the human placenta in significant amounts, but its use during pregnancy is not recommended unless the potential benefit justifies the potential risk to the fetus. It should be reserved for life-threatening hypercalcemia.

Lactation: It is not known whether calcitonin is excreted in human milk. Given that polypeptides are generally not excreted into breast milk in significant quantities and are likely digested in the infant’s gut, the risk to a nursing infant is considered low. However, caution is advised, and the decision to discontinue nursing or the drug should consider the importance of the drug to the mother.

Pediatric Considerations

Safety and effectiveness in children have not been established for most indications. Its use in pediatric patients is generally restricted to exceptional circumstances, such as juvenile Paget’s disease or severe hypercalcemia, under specialist supervision. Dosing must be carefully adjusted based on body weight or surface area.

Geriatric Considerations

No specific dosage adjustment is routinely required based on age alone. However, elderly patients often have age-related declines in renal function, which can decrease calcitonin clearance and potentially increase systemic exposure. They may also be more susceptible to dizziness, nausea, and electrolyte disturbances. The convenience of the intranasal route may be particularly advantageous in this population if manual dexterity or aversion to injections is an issue.

Renal and Hepatic Impairment

Renal Impairment: Since the kidneys are the primary site of calcitonin metabolism and excretion, renal impairment can significantly reduce clearance and increase plasma drug concentrations. In patients with end-stage renal disease, the half-life may be prolonged several-fold. While dosage adjustment guidelines are not well-defined, a lower dose or increased dosing interval should be considered in patients with moderate to severe renal impairment. Serum calcium must be monitored closely to avoid hypocalcemia.

Hepatic Impairment: The liver contributes to calcitonin metabolism, but to a lesser extent than the kidneys. Significant hepatic impairment is not expected to markedly alter pharmacokinetics, and no specific dosage adjustments are recommended. However, patients with severe liver disease may have altered albumin and calcium homeostasis, warranting careful monitoring.

Summary/Key Points

• Calcitonin is a polypeptide hormone that acts as a physiological antagonist to PTH, primarily inhibiting osteoclast-mediated bone resorption and promoting renal calcium excretion.
• Therapeutically, calcitonin salmon is preferred due to its higher receptor affinity and longer duration of action compared to the human hormone.
• Its mechanism involves binding to a G-protein-coupled receptor on osteoclasts, leading to rapid cytoskeletal retraction and inhibition of resorptive activity via cAMP and calcium signaling pathways. It also possesses central analgesic properties.
• Pharmacokinetics are route-dependent: parenteral administration offers high bioavailability and rapid onset; intranasal administration offers convenience but with low and variable systemic absorption. It is metabolized primarily in the kidneys.
• Major approved indications include Paget’s disease of bone, adjunctive management of hypercalcemia of malignancy, and treatment of postmenopausal osteoporosis (though its role here has diminished). Its analgesic effect is valuable for acute bone pain, such as from vertebral fractures.
• Common adverse effects are flushing and GI upset (injections) or nasal irritation (intranasal). A potential increased risk of malignancy with long-term use has led to restrictions on its chronic use for osteoporosis.
• Significant interactions include lithium (may decrease levels) and additive hypocalcemia with other bone-resorption inhibitors. It is contraindicated in hypersensitivity and pre-existing severe hypocalcemia.
• Special caution is required in renal impairment due to reduced clearance. Use in pregnancy, lactation, and pediatrics is generally avoided unless clearly necessary.

Clinical Pearls

• For acute hypercalcemia, calcitonin’s rapid onset makes it a useful “bridge” therapy while waiting 24-72 hours for bisphosphonates to take full effect, but anticipate potential tachyphylaxis after 2-3 days.
• The intranasal formulation should be administered in alternating nostrils daily to minimize local irritation and optimize absorption.
• In patients with osteoporosis, calcitonin’s niche is often for short-term analgesia following an acute vertebral fracture or for those intolerant to first-line antiresorptive agents, rather than as a primary long-term fracture prevention strategy.
• Pre-injection administration of an antiemetic (e.g., metoclopramide) can mitigate nausea in sensitive patients starting parenteral therapy.
• Always assess renal function prior to and during therapy, as impairment can lead to drug accumulation and prolonged hypocalcemic effects.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.